A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.

The Swiss biotech says the ERADICATE trial shows areas of differentiation for the antibiotic, like utility in pneumonia and across gram-negative and gram-positive bacteria.

Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.

Bepirovirsen made the hepatitis B virus undetectable in nearly 30% of patients in a Phase II study – but it remains to be seen whether this response be sustained once treatment with the novel antisense product ends.